Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian
immuno-oncology company, will release its fourth quarter and second half 2023
results on Thursday, 29 February 2024 at 8am CET. The results will be presented
in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein
at 3:00pm CET. 

As part of the webcast, the KOL Dr. Robert Andtbacka will share his perspective
on our clinical development program and strategy.

Dr. Andtbacka is a globally recognized surgical oncologist distinguished for his
expertise in melanoma and intratumoral immuno-oncology. With over two decades of
experience in clinical research within the field of immuno-oncology, he stands
as a pioneering leader in the field. Dr. Andtbacka served as the principal
investigator for the pivotal study that ultimately resulted in the FDA's
approval of the oncolytic virus,  talimogene laherparepvec (T-VEC), for patients
with unresectable metastatic melanoma. 


We encourage you to send us questions in advance, to be addressed during the Q&A
session. Please send your questions in an email to post@lytixbiopharma.com. 

The presentation and subsequent Q&A session will be held in English and may be
viewed live by registering here: https://forms.office.com/e/veVZgFKk2C 

A recording of the presentation will be made available on
https://www.lytixbiopharma.com/financial-reports after the presentation.


For more information, please contact: 
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com


Lytix in brief: Based in Oslo, Norway, Lytix is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic molecule representing a new
and superior therapeutic principle to boost anti-cancer immunity, with the
potential to be the ideal combination partner with other types of
immunotherapies. LTX-315 targets cancer cells and disintegrates their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens and potent immunostimulants. This mode of action allows
cytotoxic T cells to recognize, infiltrate and attack cancer cells.